Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278857

—

39ff5f3c-5525-5092-b8c9-6e603523225d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.520
  • INFLAMMATORY_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.480
  • ALLOGRAFT_REJECTION+0.470
  • IL6_JAK_STAT3_SIGNALING+0.440
  • TNFA_SIGNALING_VIA_NFKB+0.430
  • COMPLEMENT+0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
  • KRAS_SIGNALING_UP+0.360
  • COAGULATION+0.300

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.380
  • MYOGENESIS-0.330
  • MYC_TARGETS_V2-0.310
  • ADIPOGENESIS-0.290
  • BILE_ACID_METABOLISM-0.280
  • PEROXISOME-0.280
  • FATTY_ACID_METABOLISM-0.220
  • GLYCOLYSIS-0.210
  • P53_PATHWAY-0.210
  • WNT_BETA_CATENIN_SIGNALING-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR10842366
melanoma-umap@29
——0.857
2SRR934785
brain-umap@2
——0.853
3MDT-AP-2796
medullo-epn-umap@date-based
MedMedulloblastoma0.852
4SRR8518454
breast-umap@18
—D0.848
56fdba671-fb71-438f-ad62-e3d515e0222d
melanoma-umap@29
——0.841
6X7ba34ce0.93c1.4fc8.b97f.2356f342b89d
lung-landscapes@6
—cohortA10.838
7MNG751
mng-umap@100
——0.837
8d53d6bb4.fa4d.4fb5.abcb.208af064f719
lung-landscapes@6
—cohortMD20.831
9C3N-00247
lung-landscapes@6
—cohortMD20.829
10TCGA-E2-A1B1-01A-21R-A12P-07
breast-umap@18
—A0.829

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.520Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.480Idelalisib— uncovered
ALLOGRAFT_REJECTION0.470Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.440Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.430Inavolisib— uncovered
COMPLEMENT0.380Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.380Inavolisib— uncovered
KRAS_SIGNALING_UP0.360Inavolisib— uncovered
COAGULATION0.300Binimetinib— uncovered
IL2_STAT5_SIGNALING0.260Idelalisib— uncovered
ANDROGEN_RESPONSE0.210Inavolisib— uncovered
TGF_BETA_SIGNALING0.210Inavolisib— uncovered
APOPTOSIS0.190Idelalisib— uncovered
G2M_CHECKPOINT0.190Inavolisib— uncovered
ANGIOGENESIS0.180Remibrutinib— uncovered
UV_RESPONSE_DN0.170Inavolisib— uncovered
MITOTIC_SPINDLE0.140Inavolisib— uncovered
SPERMATOGENESIS0.140Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.130Idelalisib— uncovered